DoD Pancreatic Cancer Research Program anticipated funding opportunities for FY23

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY23 Defense Appropriations Act provides funding for the Pancreatic Cancer Research Program to support research of exceptional scientific merit and innovation with high impact that focuses on pancreatic cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login